{"doi":"10.1038/s41397-019-0103-3","title":"Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers","abstract":null,"journal":"The Pharmacogenomics Journal","year":2020,"id":685344,"datarank":0.41588830833596724,"base_score":2.772588722239781,"endowment":2.772588722239781,"self_citation_contribution":0.41588830833596724,"citation_network_contribution":0.0,"self_endowment_contribution":0.41588830833596724,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":15,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1522565,"name":"Miriam Saiz-Rodríguez","orcid":"0000-0002-1660-3135","position":1,"is_corresponding":false},{"id":1651057,"name":"Dolores Ochoa","orcid":null,"position":2,"is_corresponding":false},{"id":1790520,"name":"Carmen Belmonte","orcid":null,"position":3,"is_corresponding":false},{"id":1651055,"name":"Manuel Román","orcid":null,"position":4,"is_corresponding":false},{"id":1790521,"name":"Gina Mejía","orcid":null,"position":5,"is_corresponding":false},{"id":1790522,"name":"Samuel Martín-Vilchez","orcid":null,"position":6,"is_corresponding":false},{"id":1076992,"name":"Francisco Abad‐Santos","orcid":"0000-0002-6519-8885","position":7,"is_corresponding":false},{"id":1076988,"name":"Pablo Zubiaur","orcid":"0000-0002-6150-4320","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers","abstract":"Efavirenz is a non-nucleoside reverse transcriptase inhibitor used as first-line therapy for the treatment of HIV infection. Cytochrome P450 (CYP) CYP2B6 G516T (rs3745274) is a well-known predictor of efavirenz disposition. Dose adjustment based on G516T variant has been shown to be beneficial. However, this variant cannot explain the entire variability of efavirenz pharmacokinetics. In this study, we evaluated the influence of 11 single-nucleotide polymorphisms (SNPs) in CYP2B6, CYP2A6, CYP3A and ABCB1 (ATP-binding cassette sub-family B member 1) on the pharmacokinetics and safety of efavirenz after single oral dose administration to 47 healthy volunteers. We designed and validated a CYP2B6 activity score model based on two CYP2B6 SNPs (G516T and rs4803419) that predicted efavirenz disposition better than G516T alone.","is_dataset_classified":null,"base_score":2.772588722239781,"endowment":2.772588722239781,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"31628422","pmcid":null,"openalex_id":"https://openalex.org/W2980940062","authors":[],"funders":[{"funder_name":"P. Zubiaur is co-financed by Consejería de Educación, Juventud y Deporte from Comunidad de Madrid and European Social Fund.","grant_id":"","title":null}],"total_grants":1,"fwci":1.3552,"citation_percentile":0.80031402,"influential_citations":0,"citation_trend":[{"year":2020,"count":3},{"year":2021,"count":6},{"year":2022,"count":1},{"year":2023,"count":1},{"year":2024,"count":3},{"year":2026,"count":1}],"oa_status":"closed","license":"http://www.springer.com/tdm","oa_locations":[{"url":"http://www.nature.com/articles/s41397-019-0103-3.pdf","host_type":"publisher"},{"url":"http://www.nature.com/articles/s41397-019-0103-3","host_type":"publisher"},{"url":"https://doi.org/10.1038/s41397-019-0103-3","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/31628422","host_type":"repository"}],"fields_of_study":["HIV/AIDS drug development and treatment","Pharmacological Effects and Toxicity Studies","HIV/AIDS Research and Interventions","Adult","Alkynes","Benzoxazines","Cyclopropanes","Cytochrome P-450 CYP2B6","Electrocardiography","Enzyme Activation","Female","Healthy Volunteers","Heart Rate","Humans","Male","Pharmacogenetics","Pilot Projects","Polymorphism, Single Nucleotide","Reverse Transcriptase Inhibitors","Single-Blind Method","Young Adult"],"mesh_terms":["Adult","Alkynes","Cyclopropanes","Electrocardiography","Enzyme Activation","Female","Heart Rate","Humans","Male","Pharmacogenetics","Pilot Projects","Single-Blind Method","Reverse Transcriptase Inhibitors","Polymorphism, Single Nucleotide","Benzoxazines","Young Adult","Healthy Volunteers","Cytochrome P-450 CYP2B6"],"keywords":["Efavirenz","CYP2B6","Pharmacokinetics","CYP3A","Pharmacology","CYP2A6","Single-nucleotide polymorphism","Nevirapine","Reverse-transcriptase inhibitor","CYP2D6","Medicine","Internal medicine","Biology","Cytochrome P450","Virology","Human immunodeficiency virus (HIV)","CYP3A4","Viral load","Genotype","Antiretroviral therapy","Genetics","Gene","Metabolism"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"refsnp"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-18T16:24:15.850154Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}